![Bis[1,2-bis(diphenylphosphino)ethane]palladium(0) (Pd(DIPHOS)2)](/upload/1124/V65252.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Bis[1,2-bis(diphenylphosphino)ethane]palladium(0) does not have a biological target as it is a chemical catalyst rather than a pharmacologically active compound. Its function is chemical—it catalyzes carbon-carbon and carbon-heteroatom bond formation reactions. The palladium(0) center facilitates oxidative addition of aryl halides, transmetalation, and reductive elimination steps in cross-coupling reactions. The DIPHOS ligands stabilize the palladium(0) center and provide a suitable coordination environment for catalysis. The compound is not designed for therapeutic use and has no specific biological targets. Its interactions are limited to chemical substrates in organic reactions.
|
|---|---|
| ln Vitro |
A biochemical reagent called bis[1,2-bis(diphenylphosphino)ethane]palladium(0) can be utilized in life science research as an organic compound or biological material.
In vitro, bis[1,2-bis(diphenylphosphino)ethane]palladium(0) exhibits no pharmacological activity as it is a chemical catalyst. Its utility is demonstrated in catalyzing Suzuki-Miyaura coupling reactions, facilitating the coupling of aryl compounds to form biaryl complexes. The compound is also used in Buchwald-Hartwig cross-coupling, Heck reaction, Sonogashira coupling, and Stille coupling. In cell-based assays, the compound is not tested for biological activity. Its role is strictly chemical—catalyzing organic transformations in synthetic chemistry. No specific pharmacological data are available. |
| ln Vivo |
Bis[1,2-bis(diphenylphosphino)ethane]palladium(0) is not a pharmacologically active agent and does not exhibit in vivo therapeutic activity. It is used as a catalyst in organic synthesis and chemical research. The compound is not intended for human or animal exposure. It is used exclusively in laboratory and industrial settings for chemical synthesis. No therapeutic efficacy has been reported for this compound. The compound is not administered to animals in pharmacological studies and has no known physiological effects.
|
| Enzyme Assay |
In vitro assays for bis[1,2-bis(diphenylphosphino)ethane]palladium(0) focus on its catalytic activity rather than receptor binding. A standard protocol for Suzuki-Miyaura coupling involves reacting an aryl halide with an arylboronic acid in the presence of the palladium catalyst (typically 0.1-5 mol%) and a base in an appropriate solvent at elevated temperatures (80-100°C). Reaction progress is monitored by TLC or GC, and product yield is determined by purification and NMR analysis. For quality control, the compound is characterized by NMR, elemental analysis, and melting point determination. Purity is typically ≥95%.
|
| Cell Assay |
Cell-based experiments are not performed with bis[1,2-bis(diphenylphosphino)ethane]palladium(0), as it is a chemical catalyst rather than a test compound for biological activity. The compound is used exclusively in chemical synthesis and catalysis applications. No cytotoxicity or cell viability studies are conducted with this compound as it is not intended for biological applications.
|
| Animal Protocol |
In vivo animal studies are not conducted with bis[1,2-bis(diphenylphosphino)ethane]palladium(0), as it is a chemical catalyst rather than a therapeutic test article. The compound is not used in pharmacological or toxicological studies in animals. Its applications are limited to chemical synthesis and catalysis. No in vivo efficacy or safety studies have been reported for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of bis[1,2-bis(diphenylphosphino)ethane]palladium(0) are not characterized as it is not a drug substance. Based on its physicochemical properties (molecular weight 903.27, high lipophilicity, metal-containing), the compound would be expected to have very low oral bioavailability due to poor water solubility and high molecular weight. If absorbed, palladium complexes can be toxic and may interact with proteins and DNA. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for bis[1,2-bis(diphenylphosphino)ethane]palladium(0) indicate that it is a potential irritant. Palladium compounds can be toxic and may cause skin and eye irritation. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored frozen at -20°C. No acute toxicity data are available. The compound is not intended for drug, household, or other uses.
|
| Additional Infomation |
Bis[1,2-bis(diphenylphosphino)ethane]palladium(0) is a palladium catalyst used in various organic reactions including Suzuki-Miyaura coupling, Buchwald-Hartwig cross-coupling, Heck reaction, Sonogashira coupling, and Stille coupling. It serves as a highly effective catalyst for the formation of biaryl complexes. The compound is also known as Pd(DIPHOS)₂. It has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is chemical—catalyzing carbon-carbon and carbon-heteroatom bond formation through oxidative addition, transmetalation, and reductive elimination.
|
| Molecular Formula |
C52H48P4PD
|
|---|---|
| Molecular Weight |
903.25
|
| Exact Mass |
902.174
|
| CAS # |
31277-98-2
|
| PubChem CID |
2724231
|
| Appearance |
Light yellow to brown solid powder
|
| Boiling Point |
514.8ºC at 760 mmHg
|
| LogP |
10.504
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
57
|
| Complexity |
336
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)P(CCP(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4.C1=CC=C(C=C1)P(CCP(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4.[Pd]
|
| InChi Key |
FAFGMAGIYHHRKN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/2C26H24P2.Pd/c2*1-5-13-23(14-6-1)27(24-15-7-2-8-16-24)21-22-28(25-17-9-3-10-18-25)26-19-11-4-12-20-26;/h2*1-20H,21-22H2;
|
| Chemical Name |
2-diphenylphosphanylethyl(diphenyl)phosphane;palladium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1071 mL | 5.5356 mL | 11.0711 mL | |
| 5 mM | 0.2214 mL | 1.1071 mL | 2.2142 mL | |
| 10 mM | 0.1107 mL | 0.5536 mL | 1.1071 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
